Interneuron/Warner-Lambert pagoclone
Executive Summary
Warner-Lambert licenses anxiolytic pagoclone for the treatment of panic and generalized anxiety disorders from Interneuron. Under the agreement, Interneuron stands to receive $73.8 mil. in up-front and milestone payments. A portion of those payments will be given to Aventis based on Interneuron's 1994 licensing of pagoclone from Rhone-Poulenc Rorer
You may also be interested in...
AHP Redux Litigation Roster Adds Fraud Suit From Interneuron
American Home Products' lingering Redux liability now includes a fraud lawsuit brought by its former marketing partner Interneuron.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011